Results from our content library
AI-Powered Search
Sign in to search for any topic in our content library — get answers, related past year questions, and practice MCQs on the topic.
Sign in to searchIndia’s First Approved Pluvicto Radioligand Therapy
India has recently approved Pluvicto (Lutetium-177 vipivotide tetraxetan), the country's first regulatory-approved Radioligand Therapy (RLT) for the treatment of advanced prostate cancer. Developed by Novartis India, the therapy is approved for patients suffering from PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), an advanced stage of prostate cancer that continues to spread despite hormone therapy and conventional chemotherapy.
Sign up free to read the full article
Free accounts include 5 articles every month across current affairs, state notes, subject notes and more — upgrade anytime for unlimited access.
India approves Pluvicto, its first radioligand therapy for advanced prostate cancer. Novartis-developed treatment targets PSMA-positive mCRPC with precision medicine.
Keywords